Patents Represented by Attorney Martin A. Voet
  • Patent number: 7390318
    Abstract: A needleless microprotrusion system for infusion of a medicament into a patient includes a plurality of microprotrusions having a length sufficient to penetrate a stratum corneum of the patient. A chemodenervating agent is disposed for delivery by the microprotrusions and a substrate is provided for supporting the microprotrusions and conforming the microprotrusions to a patient's palm in order to enable uniform penetration of the microprotrusions into the corneum.
    Type: Grant
    Filed: November 16, 2006
    Date of Patent: June 24, 2008
    Assignee: Allergan, Inc.
    Inventors: Orest Olejnik, Robert T. Lyons, Scott J. Gerondale
  • Patent number: 7390496
    Abstract: Methods for treating a hand washing disorder by local administration of a Clostridial toxin. The local administration can be by intramuscular, transdermal, intradermal or subdermal administration of a low dose of botulinum toxin.
    Type: Grant
    Filed: April 25, 2003
    Date of Patent: June 24, 2008
    Assignee: Allergan, Inc.
    Inventor: Alan H. Ackerman
  • Patent number: 7351404
    Abstract: Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I wherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, A, B, Z, X, R1 and R2 are as defined in the specification. Such compositions are used in treating the skin or scalp of a human or non-human animal. Bimatoprost is preferred for this treatment.
    Type: Grant
    Filed: January 15, 2003
    Date of Patent: April 1, 2008
    Assignee: Allergan, Inc.
    Inventors: David F. Woodward, Amanda M. VanDenburgh
  • Patent number: 7125908
    Abstract: The present invention provides methods of treating chronic pain in a mammal by administering to the mammal an effective amount of a selective persistent sodium channel antagonist that has at least 20-fold selectivity for persistent sodium current relative to transient sodium current.
    Type: Grant
    Filed: August 27, 2004
    Date of Patent: October 24, 2006
    Assignee: Allergan, Inc.
    Inventors: George R. Ehring, Joseph S. Adorante, John E. Donello, Larry A. Wheeler, Thomas Malone
  • Patent number: 6831059
    Abstract: The present invention relates to an agent comprising a neurotoxin, methods for making the agents and methods for treating endocrine disorders, for example gonadotrophin related illnesses. Preferably, the agent comprises at least a portion of a botulinum toxin.
    Type: Grant
    Filed: March 15, 2001
    Date of Patent: December 14, 2004
    Assignee: Allergan, Inc.
    Inventor: Stephen Donovan
  • Patent number: 6827931
    Abstract: Methods for treating endocrine disorders and for inhibiting gametogenesis by intracranial administration to a human patient of a therapeutically effective amount of a neurotoxin, such as a botulinum toxin type A.
    Type: Grant
    Filed: October 20, 2000
    Date of Patent: December 7, 2004
    Assignee: Allergan, Inc.
    Inventor: Stephen Donovan
  • Patent number: 6825221
    Abstract: According to the invention there is provided a compound the formula I; wherein A, X, B, R1, R2, R3 and R4 are as defined in the specification.
    Type: Grant
    Filed: August 29, 2002
    Date of Patent: November 30, 2004
    Assignee: Allergan, Inc.
    Inventors: Robert M. Burk, Sophie Beauchemin
  • Patent number: 6821520
    Abstract: Methods for treating the hypothyroidism of Hashimoto's thyroiditis by local administration of a Clostridial toxin, such as a botulinum toxin, to the thyroid gland of a patient.
    Type: Grant
    Filed: March 15, 2002
    Date of Patent: November 23, 2004
    Assignee: Allergan, Inc.
    Inventors: Martin A. Voet, Stephen Donovan
  • Patent number: 6818779
    Abstract: A method of treating ocular hypotension, hypertension, hemorrhage, myocardial ischemia, angina pectoris, coronary contraction, cerebrovascular contraction after subarachnoidal hemorrhage, cerebral hemorrhage and asthma which comprises administering to a mammal suffering therefrom a therapeutically effective amount of a thromboxane ligand which is a compound formula I, wherein Y is (CH2)x; Z is selected from the group consisting of x is an integer of 1 or 2; n is 0 or 1; R2 is hydrogen or an alkyl radical of from 1 to 4 carbons; A is an alkylene or alkenylene radical having from two to seven carbon atoms, which radical may be substituted with one or more hydroxy, oxo, alkyloxy or alkylcarboxy groups or said alkylene or alkenylene may have one or more enchained oxa or imino radicals; B is a methyl radical or a cycloalkyl radical having from three to seven carbon atoms, or an aryl radical, selected from the group consisting of hydrocarbyl aryl and heteroaryl radicals wherein t
    Type: Grant
    Filed: August 5, 2002
    Date of Patent: November 16, 2004
    Assignee: Allergan, Inc.
    Inventors: Robert M. Burk, Achim H-P Krauss, David F. Woodward
  • Patent number: 6812240
    Abstract: The present invention provides a compound represented by the general formula I; wherein A, Ar, X, Z, n, x, y, R and R3 are as defined in the specification.
    Type: Grant
    Filed: January 26, 2004
    Date of Patent: November 2, 2004
    Assignee: Allergan, Inc.
    Inventors: David W. Old, Thang D. Dinh, Robert M. Burk
  • Patent number: 6776990
    Abstract: Methods and compositions for the treatment of acute pancreatitis in a mammal. Particular compositions comprise a binding element, a translocation element, and a therapeutic element able to prevent accumulation of digestive enzymes within the pancreas.
    Type: Grant
    Filed: April 8, 1999
    Date of Patent: August 17, 2004
    Assignee: Allergan, Inc.
    Inventors: George Sachs, Kei Roger Aoki
  • Patent number: 6773711
    Abstract: Methods for treating the hypothyroidism of Hashimoto's thyroiditis by local administration of a neurotoxin, such as a botulinum toxin, to the thyroid gland of a patient.
    Type: Grant
    Filed: October 30, 2001
    Date of Patent: August 10, 2004
    Assignee: Allergan, Inc.
    Inventors: Martin A. Voet, Stephen Donovan
  • Patent number: 6767920
    Abstract: The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound represented by the general formula I; wherein hatched lines represent the &agr; configuration, a triangle represents the &bgr; configuration, a wavy line represents the &agr; configuration or the &bgr; configuration and a dotted line represents the presence or absence of a double bond; A and B are independently selected from the group consisting of O, S and CH2; provided that at least one of A or B is S; D represents a covalent bond or CH2, O, S or NH; X is CO2R, CONR2, CH2OR, P(O)(OR)2, CONRSO2R SONR2 or Y is O, OH, OCOR2, halogen or cyano; Z is CH2 or a covalent bond; R is H or R2; R1 is H, R2, phenyl, or COR2; R2 is C1-C5 lower alkyl or alkenyl and R3 is benzothienyl, benzofuranyl, naphthyl or substituted derivatives thereof, wherein the substituents may
    Type: Grant
    Filed: January 16, 2003
    Date of Patent: July 27, 2004
    Assignee: Allergan, Inc.
    Inventors: Robert M. Burk, Mark Holoboski, Mari F. Posner
  • Patent number: 6767544
    Abstract: The present invention provides for methods of treating cardiovascular diseases in a mammal. The methods include a step of administering an effective amount of a botulinum toxin directly to a blood vessel of a mammal thereby treating a cardiovascular disease.
    Type: Grant
    Filed: April 1, 2002
    Date of Patent: July 27, 2004
    Assignee: Allergan, Inc.
    Inventors: Gregory F. Brooks, Stephen Donovan
  • Patent number: 6765012
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: September 27, 2002
    Date of Patent: July 20, 2004
    Assignee: Allergan, Inc.
    Inventors: Steven W. Andrews, Julie A. Wurster, Edward H. Wang, Thomas Malone
  • Patent number: 6759547
    Abstract: Compounds of the formula where the variables have the meaning defined in the specification are capable of reducing serum glucose levels in diabetic mammals without the undesirable side effect of reducing serum thyroxine levels.
    Type: Grant
    Filed: January 14, 2003
    Date of Patent: July 6, 2004
    Assignee: Allergan, Inc.
    Inventors: Richard L. Beard, Haiqing Yuan, Yang-Dar Yuan, Roshantha A. Chandraratna
  • Patent number: 6759546
    Abstract: Compounds of the formula where the variables have the meaning defined in the specification are capable of reducing serum glucose levels in diabetic mammals without the undesirable side effect of reducing serum thyroxine levels.
    Type: Grant
    Filed: February 4, 2003
    Date of Patent: July 6, 2004
    Assignee: Allergan, Inc.
    Inventors: Jayasree Vasudevan, Richard L. Beard, Haiqing Yuan, Roshantha A. Chandratratna
  • Patent number: 6747037
    Abstract: The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound represented by the general formula I; wherein X, Y, Z, D and R3 are as defined in the specification.
    Type: Grant
    Filed: June 6, 2003
    Date of Patent: June 8, 2004
    Assignee: Allergan, Inc.
    Inventors: David W. Old, Thang D. Dinh
  • Patent number: 6747025
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell poliferation.
    Type: Grant
    Filed: March 13, 2003
    Date of Patent: June 8, 2004
    Assignee: Allergan, Inc.
    Inventors: Steven W. Andrews, Michael E. Garst, Xialing Guo, Jonathan J. Hebert, Thomas Malone, Julie A. Wurster, Clarence Eugene Hull, III
  • Patent number: 6743424
    Abstract: A method for treating hypothyroidism by local administration of a neurotoxin, such as a botulinum toxin, to a thyroid, thereby reducing an inhibitory effect upon thyroid hormone secretion. A method for treating hyperthyroidism by local administration of a neurotoxin, such as a botulinum toxin, to a sympathetic ganglion which innervates the thyroid, thereby reducing a stimulatory effect upon thyroid hormone secretion. Methods for treating calcium metabolism disorders by local administration of a neurotoxin to modulate calcitonin secretion are also disclosed.
    Type: Grant
    Filed: November 2, 2000
    Date of Patent: June 1, 2004
    Assignee: Allergan, Inc.
    Inventor: Stephen Donovan